Olopatadine


Generic Medicine Info
Special Precautions
Not intended for contact lens-related irritation (ophth). Patient w/ other nasal disease. Pregnancy and lactation. Patient Counselling May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Ophth: Remove contact lenses prior to eye admin. Reinsert contact lenses 10 min after admin. Do not wear contact lenses if eyes are red. Improper handling may contaminate soln w/ bacteria that may cause ocular infections. Tip of the dispensing container should not be in contact w/ eye, eyelids or surrounding structures. Monitoring Parameters Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa.
Adverse Reactions
Headache, somnolence. Symptoms similar to cold syndrome and pharyngitis, blurred vision, ocular burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid oedema, or ocular pain or pruritus. Nasal: Bitter taste, epistaxis, pyrexia, rash, nasal ulceration and septal perforation, pharyngolaryngeal pain, postnasal drip, cough, UTI, upper resp tract infection.
Drug Interactions
May result in additive CNS depression w/ CNS depressants.
CIMS Class
Nasal Decongestants & Other Nasal Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
ATC Classification
R01AC08 - olopatadine ; Belongs to the class of topical antiallergic preparations, excluding corticosteroids. Used as antiallergic agents.
S01GX09 - olopatadine ; Belongs to the class of other ophthalmologic antiallergics.
Disclaimer: This information is independently developed by CIMS based on olopatadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in